Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprexs clinical development program evaluating its immunogene therapy Oncoprex„¢ for the treatment of non-small cell lung cancer.
Plasmid DNA plays an important role in the delivery of gene therapies into target cells, said Rodney Varner, Chairman and Chief Executive Officer of Genprex. Aldevron is a leading plasmid manufacturer that offers world-class laboratory and manufacturing programs. Through this agreement, we have established a GMP-validated supply of plasmid DNA vectors for our expanding clinical program evaluating the utility of Oncoprex in combination with some of the most promising new therapies for cancer.
Aldevron is honored to partner with Genprex in the development of Oncoprex, said Michael Chambers, CEO of Aldevron. This collaboration furthers our goal to provide high-quality plasmid DNA and other biologics to leading companies such as Genprex that are creating treatments that could have a significant impact on human health.
Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-SourceTM quality system. Company headquarters are in Fargo, N.D., with additional facilities in Madison, Wis., and Freiburg, Germany.
About Genprex„¢, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprexs initial product candidate, Oncoprex„¢ immunogene therapy for non-small cell lung cancer (NSCLC). Genprexs platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex„¢ has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex„¢ has also been shown to block mechanisms that create drug resistance.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of TUSC2 on cancer, the products and services we expect to receive from Aldevron and the effect of those products and services on the development of Oncoprex„¢. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of TUSC2s effect on cancer, Aldevrons ability to provide products and services to us and our ability to utilize Aldevrons products and services, the ability of Aldevrons products and services to influence the development of Oncoprex„¢, as well as the timing and success of our clinical trials and planned clinical trials of TUSC2 and Oncoprex„¢ and our other potential product candidates and the timing and success of obtaining FDA approval of Oncoprex„¢ and our other potential product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.